androgen deprivation
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
... STAMPEDE (ClinicalTrials.gov identifier NCT00268476) is a flagship multiarm, multistage, open-label, randomised controlled trial in the United Kingdom and Switzerland evaluating the combination of novel treatment ...
5
Original Article Androgen deprivation and stem cell markers in prostate cancers
... mice, androgen deprivation therapy (ADT) resulted in a temporary cessation of prostate cancer (PCa) growth, but then tumors grew faster with more malignant ...
11
Androgen deprivation therapy as backbone therapy in the management of prostate cancer
... Abstract: Androgen deprivation therapy (ADT) is well established as a backbone therapy for metastatic prostate cancer (mPCa), and both European and American guidelines emphasize the importance of ...
12
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
... testicular androgen synthesis [33, 72]. While the majority of androgen hormones are produced in the testes, about 10% of androgen synthesis occurs in the adrenal glands and peripheral tissues ...in ...
24
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy
... and androgen deprivation on MCL1 expression levels using established cell culture models of ...steroid deprivation (using 10% charcoal-stripped serum, CSS) caused an increase of MCL1 in LNCaP and to ...
18
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
... The advantages of primary androgen deprivation therapy (ADT) for localized prostate cancer continue to be con- troversial. A population-based epidemiological study indicated that primary ADT does not ...
6
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
... the androgen receptor (AR)(4); the percentage of AR positivity varies between 67 and ...with androgen deprivation therapy (ADT), such as bicalutamide, an androgen receptor antagonist with a ...
22
Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
... Androgen deprivation therapy (ADT) is an effective treatment in men with advanced metastatic PC and those with high risk tumors in combination with radiation therapy (RT) ...testicular androgen ...
14
“Androgen Deprivation Therapy for Prostate Cancer an Update on Triptorelin” by Ali Hamdan Fahad, Iraq.
... disease. Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical ...
6
Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
... Background: Both dose-escalated external beam radiotherapy (DE-EBRT) and androgen deprivation therapy (ADT) improve the outcomes in patients with intermediate-risk prostate cancer. Despite this, there are ...
5
Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes
... Abstract: Androgen deprivation therapy (ADT) constitutes the first-line treatment for patients with locally advanced tumors, recurrent or metastatic ...for androgen deprivation in pros- tate ...
8
Original Article Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers
... advanced androgen-independent prostate cancer (AIPC) from androgen-dependent prostate cancer (ADPC) remains largely ...in androgen-dependent prostate cancer ...in androgen-independent PC3 ...
11
Cardiac Structure and Function in Men with Prostate Cancer Receiving Androgen Deprivation Therapy and the Effects of Recreational Small Sided Football Training: A Randomized Controlled Trial
... Androgen deprivation therapy (ADT) is a cornerstone in prostate cancer (PCa) management that prolongs PCa-free and overall survival. However, ADT is as- sociated with increased risk of cardiovascular ...
15
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
... of androgen depri- vation therapy was determined as well as the duration of ...of androgen deprivation therapy included steroidal and non-steroidal anti-androgens, LHRH analo- gues, conjugated ...
6
Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
... adjuvant androgen deprivation therapy was started within 12 weeks of radical ...combined androgen blockade consisting of orchiectomy or an LHRH ana- log together with ...drogen deprivation ...
6
The early effects of rapid androgen deprivation on human prostate cancer
... The androgen receptor (AR) is the dominant growth factor in prostate cancer ...serum androgen, with reduced levels of intraprostatic androgen at ...known androgen-regulated genes (TMPRSS2, ...
5
Cardiovascular health in men on androgen deprivation therapy for prostate cancer
... Moreover, cardiovascular disease is now considered a leading cause of death for patients with cancers of the breast, prostate, colon-rectum and endometrium Baade et al., 2006; Patnaik et[r] ...
330
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
... PCa cells with low or null PSA expression have an im- portant role in the progression to CRPC: their increase correlated with patients ’ shorter survival [10] and ADT led to their expansion [11, 12]. Accordingly, among ...
14
Biopsychosocial impact of prostate cancer and androgen deprivation therapy
... CUAJ ? October 2017 ? Volume 11, Issue 10 ? 2017 Canadian Urological Association Original research 338 Cite as Can Urol Assoc J 2017;11(10) 338 43 http //dx doi org/10 5489/cuaj 4499 Abstract Introduc[.] ...
6
Androgen deprivation therapy prevents bladder cancer recurrence
... that androgen receptor (AR) signals are involved in BC development ...that androgen-mediated activation of AR signaling would promote bladder tumorigenesis and cancer ...
10